Javascript must be enabled to continue!
Increased levels of tissue inhibitor of metalloproteinase‐1 in human hepatocellular carcinoma
View through CrossRef
Abstract:
Background: Invasion and metastasis of hepatocellular carcinoma (HCC) are regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). However, the role of TIMPs in these processes is not clear.Aim: To examine the potential involvement of TIMP‐1 in HCC and the association between TIMP‐1 and clinical outcome of patients with HCC.Methods: The study included 91 patients who underwent surgical removal of HCC. TIMP‐1 concentrations in the supernatant of tissue homogenates of HCC and non‐neoplastic liver were measured by enzyme immunoassay. The relationships between TIMP‐1 concentration and various clinicopathological features and recurrence of HCC after surgical operation were examined.Results: The mean level of TIMP‐1 in HCC (486±610 ng/mg protein, ±SD) was significantly higher than in the non‐neoplastic liver (75±69, P<0.0001). The median level of TIMP‐1 in poorly differentiated HCCs (701 ng/mg protein) was significantly higher than in well‐ (80) and moderately (172) differentiated HCCs (P=0.0047 and P=0.0082, respectively). TIMP‐1 level in liver cirrhosis was higher than in chronic hepatitis (P=0.0015). TIMP‐1 levels in HCC did not influence the recurrence rate of HCC.Conclusions: TIMP‐1 concentration in HCC was higher than in non‐neoplastic liver and correlated with the differentiation grade of HCCs. However, tissue TIMP‐1 concentration does not seem to be an important determinant of HCC recurrence.
Title: Increased levels of tissue inhibitor of metalloproteinase‐1 in human hepatocellular carcinoma
Description:
Abstract:
Background: Invasion and metastasis of hepatocellular carcinoma (HCC) are regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).
However, the role of TIMPs in these processes is not clear.
Aim: To examine the potential involvement of TIMP‐1 in HCC and the association between TIMP‐1 and clinical outcome of patients with HCC.
Methods: The study included 91 patients who underwent surgical removal of HCC.
TIMP‐1 concentrations in the supernatant of tissue homogenates of HCC and non‐neoplastic liver were measured by enzyme immunoassay.
The relationships between TIMP‐1 concentration and various clinicopathological features and recurrence of HCC after surgical operation were examined.
Results: The mean level of TIMP‐1 in HCC (486±610 ng/mg protein, ±SD) was significantly higher than in the non‐neoplastic liver (75±69, P<0.
0001).
The median level of TIMP‐1 in poorly differentiated HCCs (701 ng/mg protein) was significantly higher than in well‐ (80) and moderately (172) differentiated HCCs (P=0.
0047 and P=0.
0082, respectively).
TIMP‐1 level in liver cirrhosis was higher than in chronic hepatitis (P=0.
0015).
TIMP‐1 levels in HCC did not influence the recurrence rate of HCC.
Conclusions: TIMP‐1 concentration in HCC was higher than in non‐neoplastic liver and correlated with the differentiation grade of HCCs.
However, tissue TIMP‐1 concentration does not seem to be an important determinant of HCC recurrence.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Tissue Inhibitor of Metalloproteinase 3 as a potential staging biomarker in hepatocellular carcinoma
Tissue Inhibitor of Metalloproteinase 3 as a potential staging biomarker in hepatocellular carcinoma
Objective: To assess the potential role of tissue inhibitor of metalloproteinase 3 as a staging marker of hepatocellular carcinoma.Method: The experimental study was conducted at F...
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
This paper aims to evaluate the GALAD score in diagnosing hepatocellular carcinoma. The paper conducted a retrospective study of 86 Hepatocellular Carcinoma patients who underwent ...
Gene Expression Characteristics of Liver Tissue Reveal the Underlying Pathogenesis of Hepatocellular Carcinoma
Gene Expression Characteristics of Liver Tissue Reveal the Underlying Pathogenesis of Hepatocellular Carcinoma
Background. Hepatocellular carcinoma (HCC) is high‐mortality primary liver cancer and the most common malignant tumor in the world. This study is based on a hepatocellular carcinom...
PERBANDINGAN INDEKS ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX (APRI) PADA PASIEN SIROSIS HEPATIS DAN KARSINOMA HEPATOSELULER
PERBANDINGAN INDEKS ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX (APRI) PADA PASIEN SIROSIS HEPATIS DAN KARSINOMA HEPATOSELULER
ABSTRAK
Sirosis hepatis dianggap sebagai kondisi sebelum terjadinya karsinoma hepatoseluler. Sirosis hepatis dan karsinoma hepatoseluler perlu dideteksi lebih awal dengan men...
Unusual Metastasis from Follicular Thyroid Carcinoma: A Case Report and Literature Review
Unusual Metastasis from Follicular Thyroid Carcinoma: A Case Report and Literature Review
Abstract
Introduction
Follicular thyroid carcinoma (FTC) is a type of well-differentiated thyroid carcinoma. It has a poorer prognosis, is more metastatic, and has characteristics ...

